Pilot evaluation of mirtazapine for the treatment of hot flashes

Domingo G. Perez, Charles Lawrence Loprinzi, Debra L. Barton, Barbara A Pockaj, Jeff A Sloan, Paul J. Novotny, Bradley J. Christensen

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

This prospective, single-arm, pilot clinical trial, developed to evaluate the efficacy and tolerability of mirtazapine for alleviating hot flashes, was conducted between May 2001 and January 2002. Patients' baseline characteristics were collected during the first week of the study. At the beginning of the second week, patients were started on mirtazapine at a dose of 7.5 mg at bedtime. The dose of mirtazapine was then increased to 15 mg at week 3 and to 30 mg at week 4. For week 5, patients could choose whether to take 15 mg/d or 30 mg/d. Data were obtained primarily from patient-completed questionnaires. Data from 22 evaluable women were available. For the 16 patients who completed the study, the median reductions in total daily hot flashes and weekly hot-flash scores from their baselines were 52.5% and 59.5%, respectively. Patients reported improvements in tension, trouble sleeping, abnormal sweating, distress from hot flashes, satisfaction with hot-flash control, overall quality of life, and impact of hot flashes on quality of life. Patients also reported increases in appetite and dry mouth. Although data from a double-blind, placebo-controlled clinical trial would be necessary to more definitively elucidate the efficacy and toxicity of mirtazapine in patients with hot flashes, the available data suggest that mirtazapine is a reasonable treatment to consider in patients with hot flashes, particularly in those with anxiety and sleep disturbances.

Original languageEnglish (US)
Pages (from-to)50-56
Number of pages7
JournalJournal of Supportive Oncology
Volume2
Issue number1
StatePublished - Jan 2004

Fingerprint

Hot Flashes
Therapeutics
Quality of Life
mirtazapine
Sweating
Controlled Clinical Trials
Appetite
Mouth
Sleep
Anxiety
Placebos
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pilot evaluation of mirtazapine for the treatment of hot flashes. / Perez, Domingo G.; Loprinzi, Charles Lawrence; Barton, Debra L.; Pockaj, Barbara A; Sloan, Jeff A; Novotny, Paul J.; Christensen, Bradley J.

In: Journal of Supportive Oncology, Vol. 2, No. 1, 01.2004, p. 50-56.

Research output: Contribution to journalArticle

Perez, DG, Loprinzi, CL, Barton, DL, Pockaj, BA, Sloan, JA, Novotny, PJ & Christensen, BJ 2004, 'Pilot evaluation of mirtazapine for the treatment of hot flashes', Journal of Supportive Oncology, vol. 2, no. 1, pp. 50-56.
Perez, Domingo G. ; Loprinzi, Charles Lawrence ; Barton, Debra L. ; Pockaj, Barbara A ; Sloan, Jeff A ; Novotny, Paul J. ; Christensen, Bradley J. / Pilot evaluation of mirtazapine for the treatment of hot flashes. In: Journal of Supportive Oncology. 2004 ; Vol. 2, No. 1. pp. 50-56.
@article{6cf400613244414b87e1b62ddcfe7e2a,
title = "Pilot evaluation of mirtazapine for the treatment of hot flashes",
abstract = "This prospective, single-arm, pilot clinical trial, developed to evaluate the efficacy and tolerability of mirtazapine for alleviating hot flashes, was conducted between May 2001 and January 2002. Patients' baseline characteristics were collected during the first week of the study. At the beginning of the second week, patients were started on mirtazapine at a dose of 7.5 mg at bedtime. The dose of mirtazapine was then increased to 15 mg at week 3 and to 30 mg at week 4. For week 5, patients could choose whether to take 15 mg/d or 30 mg/d. Data were obtained primarily from patient-completed questionnaires. Data from 22 evaluable women were available. For the 16 patients who completed the study, the median reductions in total daily hot flashes and weekly hot-flash scores from their baselines were 52.5{\%} and 59.5{\%}, respectively. Patients reported improvements in tension, trouble sleeping, abnormal sweating, distress from hot flashes, satisfaction with hot-flash control, overall quality of life, and impact of hot flashes on quality of life. Patients also reported increases in appetite and dry mouth. Although data from a double-blind, placebo-controlled clinical trial would be necessary to more definitively elucidate the efficacy and toxicity of mirtazapine in patients with hot flashes, the available data suggest that mirtazapine is a reasonable treatment to consider in patients with hot flashes, particularly in those with anxiety and sleep disturbances.",
author = "Perez, {Domingo G.} and Loprinzi, {Charles Lawrence} and Barton, {Debra L.} and Pockaj, {Barbara A} and Sloan, {Jeff A} and Novotny, {Paul J.} and Christensen, {Bradley J.}",
year = "2004",
month = "1",
language = "English (US)",
volume = "2",
pages = "50--56",
journal = "Journal of Supportive Oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "1",

}

TY - JOUR

T1 - Pilot evaluation of mirtazapine for the treatment of hot flashes

AU - Perez, Domingo G.

AU - Loprinzi, Charles Lawrence

AU - Barton, Debra L.

AU - Pockaj, Barbara A

AU - Sloan, Jeff A

AU - Novotny, Paul J.

AU - Christensen, Bradley J.

PY - 2004/1

Y1 - 2004/1

N2 - This prospective, single-arm, pilot clinical trial, developed to evaluate the efficacy and tolerability of mirtazapine for alleviating hot flashes, was conducted between May 2001 and January 2002. Patients' baseline characteristics were collected during the first week of the study. At the beginning of the second week, patients were started on mirtazapine at a dose of 7.5 mg at bedtime. The dose of mirtazapine was then increased to 15 mg at week 3 and to 30 mg at week 4. For week 5, patients could choose whether to take 15 mg/d or 30 mg/d. Data were obtained primarily from patient-completed questionnaires. Data from 22 evaluable women were available. For the 16 patients who completed the study, the median reductions in total daily hot flashes and weekly hot-flash scores from their baselines were 52.5% and 59.5%, respectively. Patients reported improvements in tension, trouble sleeping, abnormal sweating, distress from hot flashes, satisfaction with hot-flash control, overall quality of life, and impact of hot flashes on quality of life. Patients also reported increases in appetite and dry mouth. Although data from a double-blind, placebo-controlled clinical trial would be necessary to more definitively elucidate the efficacy and toxicity of mirtazapine in patients with hot flashes, the available data suggest that mirtazapine is a reasonable treatment to consider in patients with hot flashes, particularly in those with anxiety and sleep disturbances.

AB - This prospective, single-arm, pilot clinical trial, developed to evaluate the efficacy and tolerability of mirtazapine for alleviating hot flashes, was conducted between May 2001 and January 2002. Patients' baseline characteristics were collected during the first week of the study. At the beginning of the second week, patients were started on mirtazapine at a dose of 7.5 mg at bedtime. The dose of mirtazapine was then increased to 15 mg at week 3 and to 30 mg at week 4. For week 5, patients could choose whether to take 15 mg/d or 30 mg/d. Data were obtained primarily from patient-completed questionnaires. Data from 22 evaluable women were available. For the 16 patients who completed the study, the median reductions in total daily hot flashes and weekly hot-flash scores from their baselines were 52.5% and 59.5%, respectively. Patients reported improvements in tension, trouble sleeping, abnormal sweating, distress from hot flashes, satisfaction with hot-flash control, overall quality of life, and impact of hot flashes on quality of life. Patients also reported increases in appetite and dry mouth. Although data from a double-blind, placebo-controlled clinical trial would be necessary to more definitively elucidate the efficacy and toxicity of mirtazapine in patients with hot flashes, the available data suggest that mirtazapine is a reasonable treatment to consider in patients with hot flashes, particularly in those with anxiety and sleep disturbances.

UR - http://www.scopus.com/inward/record.url?scp=4644348385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644348385&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 50

EP - 56

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 1

ER -